Innate Pharma 2021 Financial Calendar
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced its 2021 financial calendar. Key dates include:
- March 18, 2021: 2020 financial statements
- May 11, 2021: Q1 2021 revenue
- May 28, 2021: Annual General Shareholders Meeting
- September 15, 2021: Half-year financial statements
- November 16, 2021: Q3 2021 revenue
Reports will be released before market open CET. Innate Pharma focuses on oncology, aiming to enhance patient outcomes through innovative immune-based therapies.
- Scheduled release of financial reports may enhance investor confidence.
- Focus on oncology with a commercial-stage product, Lumoxiti, indicating a stable revenue stream.
- None.
MARSEILLE, France, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2021 financial calendar:
| March 18, 2021: | Publication of 2020 financial statements |
| May 11, 2021: | Publication of revenue for 1Q2021 |
| May 28, 2021: | Annual General Shareholders Meeting |
| September 15, 2021: | Publication of half year financial statements |
| November 16, 2021: | Publication of revenue for 3Q2021 |
All financial reports are released before market open CET.
All corporate information, such as the Company’s financial statements and corporate presentations, is available on https://investors.innate-pharma.com.
About Innate Pharma:
Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com
Information about Innate Pharma shares:
| ISIN code Ticker code LEI | FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
| Investors Innate Pharma Tel.: +33 (0)4 30 30 30 30 investors@innate-pharma.com | Media Innate Pharma Tracy Rossin (Global/US) Tel.: +1 240 801 0076 Tracy.Rossin@innate-pharma.com |
| ATCG Press Marie Puvieux (France) Tel.: +33 (0)9 81 87 46 72 innate-pharma@atcg-partners.com |
FAQ
What are the important dates in Innate Pharma's 2021 financial calendar?
How often will Innate Pharma release financial reports in 2021?
What is Innate Pharma's main focus in the biotech sector?
What is Lumoxiti and its significance for Innate Pharma?
When is the Annual General Shareholders Meeting for Innate Pharma?
